论文部分内容阅读
ＣＹＦＲＡ２１－１是细胞角蛋白１９的片段（ＣＫ１９）。免疫放射法（ＩＲＭＡ）测定１３３例肺癌患者血清中ＣＹＦＲＡ２１－１水平，与血清神经元特异性烯醇化酶（ＮＳＥ）作比较，初步观察了５例非小细胞肺癌患者血清ＣＹＦＲＡ２１－１在治疗过程中的动态变化。结果表明肺癌患者血清ＣＹＦＲＡ２１－１水平明显高于肺良性疾患组（Ｐ＜０．００１）和正常对照组（Ｐ＜０．００１）；在肺癌患者，血清ＣＹＦＲＡ２１－１水平升高主要出现在非小细胞肺癌组，尤其是鳞癌组，阳性诊断率分别为５２．８％和７２．１％，明显高于小细胞肺癌组（２７．３％）（Ｐ＜０．０１，Ｐ＜０．００１），在非小细胞肺癌组，血清ＣＹＦＲＡ２１－１与肿瘤临床分期相关。其阳性诊断率１期为３５．３％，Ⅰ期为５５．６％，Ⅱ期为６３．６％，Ⅳ期为７３．３％；血清ＮＳＥ水平的升高以小细胞肺癌为主，阳性率为５９．１％，高于非小细胞肺癌组（２１．３％，Ｐ＜０．００１），鳞癌组（２７．９％，Ｐ＜０．００１）。联合检测血清ＣＹＦＲＡ２１－１和ＮＳＥ可将整体肺癌的阳性诊断率提高至６１．７％。对血清ＣＹＦＲＡ２１－１的动态监测显示肿瘤进展时其水平持续升高。病人预后较差，水平的下降提示疾病缓解。检?
CYFRA21-1 is a fragment of cytokeratin 19 (CK19). IRMA was used to measure the serum CYFRA21-1 level in 133 lung cancer patients and compared with serum neuron-specific enolase (NSE). The serum CYFRA21-1 in 5 patients with non-small cell lung cancer was initially observed during treatment. Dynamic changes in the. The results showed that serum CYFRA21-1 levels in lung cancer patients were significantly higher than those in benign lung disease group (P<0.001) and normal control group (P<0.001); in lung cancer patients, serum CYFRA21-1 levels increased mainly in non- In the small cell lung cancer group, especially the squamous cell carcinoma group, the positive diagnostic rates were 52.8% and 72.1%, respectively, which was significantly higher than that in the small cell lung cancer group (27.3%) (P<0.01, P<0. 001) In the non-small cell lung cancer group, serum CYFRA21-1 is associated with the clinical stage of the tumor. The positive diagnostic rate was 35.3% in the first phase, 55.6% in the phase I, 63.6% in the phase II, and 73.3% in the phase IV; the elevation of serum NSE levels was mainly in small cell lung cancer, positive The rate was 59.1%, higher in the non-small cell lung cancer group (21.3%, P<0.001) and in the squamous cell carcinoma group (27.9%, P<0.001). Combined detection of serum CYFRA21-1 and NSE increased the positive diagnosis rate of lung cancer to 61.7%. Dynamic monitoring of serum CYFRA21-1 shows that the level of tumor progression continues to increase. The patient’s prognosis is poor, and the decline in the level suggests a remission of the disease. Inspection?